

12th

Canadian Kidney Cancer Forum

October 13-15, 2022

Hotel X by Library Hotel Collection
Toronto, ON

KCRNC

KIDNEY CANCER RESEARCH
NETWORK OF CANADA

RRCRC

RÉSEAU DE RECHERCHE SUR LE
CANCER DU REIN DU CANADA



PROGRAM



#CKCF22



12th

Canadian Kidney Cancer Forum

THURSDAY, OCTOBER 13, 2022

- 1000 – 1400 CKCis Steering Committee Meeting (*Invitation Only*)
Humber Park (2nd floor)
- 1830 – 1930 **Networking Dinner Event**
Princes' Gate West (3rd floor)
- 1930 – 1935 **Welcome & Introduction of Program Co-Chairs**
Princes' Gate East (3rd floor)
Anil Kapoor
- 1935 – 1945 **Welcome and Overview of Program**
Aly-Khan Lalani, Luke Lavallée
- 1945 – 2010 **A Decade of Progress: Individualizing Frontline Treatment in RCC**
Rana McKay, *Intro by Aly-Khan Lalani*
- 2010 - 2020 Discussion & Q/A
- 2020 - 2045 **Novel endpoints for IO-based clinical trials**
Meredith Regan, *Intro by Luke Lavallée*
- 2045 - 2100 Discussion & Q/A
- 2100 - 2300 **Networking Event**
Trillium Park Studio (3rd floor)

October 13-15 2022 • Hotel X by Library Hotel Collection

12th

Canadian Kidney Cancer Forum

FRIDAY, OCTOBER 14, 2022

0700 – 0800 **Networking Breakfast**
Princes' Gate West (3rd floor)

0700 – 0800 CKCis Operations Committee Meeting
(Invitation Only)
Humber Park (2nd floor)

AM SESSION 1 (0800 - 0945)

Moderators: Tony Finelli, Kristen McAlpine
Princes' Gate East (3rd floor)

0800 - 0825 **Predicting cancer recurrence following surgery**
Rodney Breau

0825 - 0835 Discussion & Q/A

0835 - 0900 **Non-surgical approaches of primary RCC**
Anand Swaminath

0900 - 0910 Discussion & Q/A

0910 - 0935 **Approach to cystic renal masses, SOCRATIC Trial
update, and CUA Guideline**
Patrick Richard

0935 - 0945 Discussion & Q/A

0945 – 1000 **Networking Health Break**
Princes' Gate West (3rd floor)

AM SESSION 2 (1000 - 1150)

Moderators: Simon Tanguay, Jeffrey Graham

1000 - 1025 **Tumour board panel: Challenging localized cases**
Panel: Bimal Bhindi (Lead), Rahul Bansal, Scott Morgan

1025 - 1035 Discussion & Q/A

1035 - 1100 **Should we reassess prognostic factors in the era of
IO-based therapies for advanced RCC?**
Meredith Regan

1100 - 1110 Discussion & Q/A

October 13-15 2022 • Hotel X by Library Hotel Collection

12th

Canadian Kidney Cancer Forum

- 1110 - 1150 **Debate: Is adjuvant IO therapy ready for prime time?**
YAY: Rana McKay, NAY: Anil Kapoor
- 1150 - 1200 Discussion & Q/A
- 1200 - 1250 **Networking Lunch and Group Photo Opportunity**
Princes' Gate West (3rd floor)

PM SESSION (1250 - 1350)

Moderators: Bimal Bhindi, Neil Reaume

- 1250 - 1310 CKCis update report
Naveen Basappa, Rodney Breau
- 1310 - 1320 Discussion & Q/A
- 1320 - 1340 **Kidney Cancer Canada patient advocacy updates**
Bob Bick
- 1340 - 1350 Discussion & Q/A
- 1350 - 1435 **KCRNC-KCC-CUASF 2022 Abstract Presentations**
- 1435 - 1700 **Networking Activity FIFA**
Activity is offsite and bus will depart lobby at 14:45
for Ballsports Polson Pier.
Address: 176 Cherry St. Toronto, ON M5A 3L2
- 1700 - 1800 Group Returns
- 1930 - 2230 **Networking Reception & Banquet**
Newfort Hall (Ground Level)
followed by networking event in Trillium Park Studio (3rd floor)

October 13-15 2022 • Hotel X by Library Hotel Collection

12th

Canadian Kidney Cancer Forum

SATURDAY, OCTOBER 15, 2022

0700 - 0800 **Networking Breakfast**
Princes' Gate West (3rd floor)

AM SESSION (0800 - 1010)

Moderators: Georg Bjarnason, Christina Canil
Princes' Gate East (3rd floor)

0800 - 0825 **Subsequent line options for RCC: Using RWE to inform choices**
Jeffrey Graham

0825 - 0835 Discussion & Q/A

0835 - 0900 **Clinical trial updates in RCC**
Christian Kollmannsberger

0900 - 0910 Discussion & Q/A

0910 - 0935 **Germline testing and genetics update in RCC**
Emily Thain

0935 - 0945 Discussion & Q/A

0945 - 1010 **Tumour board panel: Challenging advanced cases**
Panel: Dominick Bossé (Lead), Shaan Dudani,
Jean-Baptiste Lattouf

1010 - 1025 **Networking Health Break**
Princes' Gate West

1025 - 1155 **Consensus meeting - adjuvant therapy**
(Open to HCPs only: closed to Industry)
Aly-Khan Lalani, Luke Lavallée

1155 - 1200 Closing remarks

October 13-15 2022 • Hotel X by Library Hotel Collection

BIOGRAPHIES

Chair



Anil Kapoor

Dr. Kapoor is currently Professor of Surgery (Urology & Oncology) at McMaster University/ St. Joseph's Hospital in Hamilton, Ontario, Canada. He obtained his MD from Dalhousie University. He is a Fellow of the Royal College of Physicians and Surgeons of Canada and a Diplomate of American Board of Urology. He is certified by the American Society of Transplant Surgeons, having obtained post-graduate training from the Cleveland Clinic Foundation in Renal Transplantation, Renal-Vascular surgery, and GU Oncology.

Dr. Kapoor is current Director of the Urologic Cancer Centre for Research & Innovation (UCCRI) at St. Joseph's Hamilton, Head of the Genito-Urinary Oncology program at the Juravinski Cancer Centre, Co-Chair of the NCIC Kidney Cancer Disease Group, and Chair of the Kidney Cancer Research Network of Canada (KCRNC). He is a member of the Board of Directors of Kidney Cancer Canada (KCC). He has published over 300 peer-reviewed papers, 12 book chapters and over 200 abstracts in the fields of genito-urinary oncology (prostate cancer and kidney cancer), kidney transplantation, and urologic laparoscopy. He is current Head of the Clinical Trials Group at the McMaster Institute of Urology (MIU) and established the Kidney Cancer Centre at McMaster University in 2009.

BIOGRAPHIES

Scientific Program Co-Chairs



Aly-Khan A. Lalani

Dr. Lalani is an Assistant Professor at McMaster University and a Medical Oncologist at the Juravinski Cancer Centre. After residency training, he was awarded the TD Insurance Meloche Monnex & Alberta Medical Association Scholarship. He pursued a Fellowship in Genitourinary Oncology at Dana-Farber Cancer Institute in Boston, mentored by Dr. Toni Choueiri. He has also completed the Program in Clinical Effectiveness at the Harvard T.H. Chan School of Public Health. He is a member of the Escarpment Cancer Research Institute, and an Associate Member of the Centre for Discovery in Cancer Research (CDCR) at McMaster University.

His academic interests include clinical trial design and translational work for genitourinary malignancies. He was awarded the Elizabeth Eisenhower Early Drug Development Young Investigator Award 2022, from the Canadian Cancer Trials Group. He is the lead PI for the CYTOSHRINK clinical trial.



Luke Lavallée

Dr. Lavallée is a urologic oncologist, associate professor and scientist at The Ottawa Hospital and Ottawa Hospital Research Institute. He holds a University of Ottawa Research Chair in Surgery. His research programs aim to improve quality of care for patients with kidney cancer. He is the author of two patient decision aids in kidney cancer focusing on treatment of small renal masses and surgery. He holds peer-reviewed funding from kidney, bladder, and venous thromboembolism research organizations, and has published 150 scientific articles. In 2015 he claimed the O-Town Touchdown Fantasy Football Championship - defeating, amongst others, Dr. Rodney Breau.

BIOGRAPHIES

Invited guest speaker



Rana R. McKay

Dr. McKay is an Associate Professor of Medicine and Urology at the University of California San Diego, Associate Director of Translational Sciences, and Co-Leader of the Genitourinary Oncology Program at the Moores Cancer Center. She is a medical oncologist who specializes in treating people with urogenital cancers. Her research interests include advanced therapeutics, precision medicine, and biomarker development. Her work has appeared in peer-reviewed publications such as *The New England Journal of Medicine*, *Nature*, *Lancet*, *Journal of Clinical Oncology*, *Clinical Cancer Research*, *Cancer*, among others. She is a member of the NCI Renal Task Force, NRG RCC Cadre Leader, and Alliance Advanced Prostate Cancer, Cadre Leader, and member of the NCCN Prostate Cancer Guidelines panel. Dr. McKay earned her medical degree at the University of Florida College of Medicine before completing her residency at Johns Hopkins Hospital. She completed a fellowship in Oncology/Hematology at the Dana-Farber Cancer Institute.

BIOGRAPHIES

Invited guest speaker



Meredith M. Regan

Dr. Regan is Associate Professor, Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute (DFCI) and Associate Professor of Medicine, Harvard Medical School.

For over 20 years, Dr. Regan's research has focused on clinical trials and clinical-translational research to inform patient care and treatment selection in breast and genitourinary cancers. More recently her research includes clinical trial endpoints.

Dr. Regan is Director of the Statistics and Data Management Center for the International Breast Cancer Study Group (IBCSG) and co-leads the IBCSG's TEXT and SOFT phase 3 clinical trials of adjuvant endocrine therapy for premenopausal women with endocrine-responsive early breast cancer.

She is also a researcher in the DFCI inflammatory breast cancer program.

Her research in genitourinary cancers has ranged from collaborations in preclinical studies, to clinical trials and observational clinical studies in prostate and kidney cancers; and health outcomes as past director of data coordinating center for the Prostate Cancer Outcomes and Satisfaction with Treatment Quality (PROSTQA) Consortium which (led by Dr. Martin Sanda).

More recently, she was the statistical lead for the Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) Working Group (led by Dr. Christopher Sweeney).

Dr. Regan is active with cancer societies. She is a past co-director of the AACR-led Methods in Clinical Cancer Research "Vail" course. She is a Fellow of ASCO, with membership on ASCO grant review and annual meeting program committees. She is co-author of national and international clinical guidelines of ASCO, ESMO, SITC, and St. Gallen consensus for treatment of early breast cancer. She's now co-chair of a US NCI working group "neoSTEEP" defining endpoints and design for neoadjuvant clinical trials for early breast cancer.

October 13-15 2022 • Hotel X by Library Hotel Collection

BIOGRAPHIES

Invited Speakers



Naveen S. Basappa

Dr. Basappa is a Medical Oncologist at the Cross Cancer Institute in Edmonton, Alberta. He is an Assistant Professor in the Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta. He is currently the Genitourinary Cancers Tumor Group Lead of Northern Alberta and the site Genitourinary Cancers Medical Oncology Clinical and Research Lead at the Cross Cancer Institute.

Dr. Basappa obtained his MD at the University of Alberta. He received training in Internal Medicine at the University of Toronto in Toronto, Ontario and later went on to complete his subspecialty training in Medical Oncology at the University of Alberta in Edmonton, Alberta. He followed this up with an Experimental Therapeutics Fellowship with a focus on Genitourinary Cancers at Cleveland Clinic in Cleveland, Ohio, USA.

Dr. Basappa's research interests focus on the management of genitourinary malignancies, including kidney, bladder, and prostate cancer. He is the principle or co-investigator of multiple national and international clinical trials and actively conducts clinical research in the field of genitourinary malignancies.

BIOGRAPHIES



Bob Bick

Robert Bick is a Health Policy Consultant with extensive public affairs, government relations, payer relations and patient advocacy expertise. He specializes in advising and assisting clients on strengthening their relationships with government and designing and implementing strategies to see favourable patient access to newly available treatment options and medical devices.

Robert has worked extensively with health industry clients, patient advocacy groups, clinicians, researchers and professional health care associations. Prior to founding his own consulting practice, Robert was a Senior Consultant with ICON/Oxford Outcomes, an international health outcomes research agency. Robert also has 10 years of public sector experience, including 2 years as Executive Officer Economic and Labour Policy in Cabinet Office of the Ontario Government and a number of years as senior political staff to an Ontario cabinet minister.

Robert is a charter board member of Kidney Cancer Canada, and the co-Lead and co-founder of the CanCertainty Coalition which consists of a coalition of 35 national cancer patient groups and oncology professionals seeking to have take-home cancer drugs universally reimbursed in Ontario and the Atlantic provinces.



Rodney Breau

Dr. Breau is a Surgical Oncologist, Scientist, and Professor of Urology at The University of Ottawa/Ottawa Hospital Research Institute. He attended medical school at Dalhousie University and urology residency at the University of Ottawa. He completed his Urologic Oncology and Robotic Surgery Fellowship at Mayo Clinic and received a Master of Science in Clinical and Translational Research from Mayo School of Graduate Medical Education. Dr. Breau serves on numerous American Urological Association, Canadian Urological Association, and Cancer Care Ontario leadership committees. He is the primary investigator of several multicenter surgical trials in urologic oncology and is the co-lead of national cohort studies in kidney and bladder cancer.

BIOGRAPHIES



Jeffrey Graham

Dr. Graham completed medical school at the University of Manitoba in 2012. He subsequently completed residency training in Internal Medicine followed by subspecialty training in Medical Oncology at CancerCare Manitoba. He went on to pursue a clinical and research fellowship in genitourinary oncology at the University of Calgary, with a research focus on advanced kidney cancer. He completed a master in public health (MPH) in epidemiology at Harvard University. He is currently a staff medical oncologist at CancerCare Manitoba, assistant professor in the department of internal medicine at the University of Manitoba, and affiliate scientist at the CancerCare Manitoba Research Institute.



Christian Kollmannsberger

Dr. Kollmannsberger is staff medical oncologist at the British Columbia Cancer Agency (BCCA) Vancouver Cancer Centre and Clinical Professor at the University of British Columbia. He graduated from the Technical University in Munich, Germany and received his clinical training in internal medicine, haematology and medical oncology, mainly at University of Tuebingen, Germany. Dr. Kollmannsberger's research is focused on genito-urinary malignancies with a special interest in testicular and renal cell cancer. Nationally and internationally, he has contributed to numerous trials in the field of renal cell carcinoma and testicular cancer. He has authored or co-authored more than 250 publications. He has repeatedly served as faculty for the Annual meeting of the American Society of Clinical Oncology (ASCO), the ASCO Genitourinary Cancers Symposium, and the Annual Meeting of the European Society of Medical Oncology (ESMO). Currently, Dr. Kollmannsberger serves as chair of the BC Cancer Genitourinary Cancers Tumor Group, chair for the Genitourinary Clinical Trials Unit and as Head, Department of Medical Oncology at BC Cancer Vancouver Centre.

BIOGRAPHIES



Patrick Richard

Dr. Richard obtained his MD from the Université de Sherbrooke and completed his urology residency at Sherbrooke and McGill University. He then completed a urologic oncology fellowship at the Princess Margaret Cancer Centre and a Master's in clinical epidemiology at the Institute of Health Policy, Management and Evaluation. He is an associate professor and research clinician at the Université de Sherbrooke since 2016. He was awarded the FRSQ Clinician Scientist Research Scholar- Junior 2 Award in 2022 and holds the CRMUS research chair in kidney cancer. He is the author of several manuscripts, book chapters and guidelines and has received numerous grants to study prostate and kidney cancers. Dr. Richard research program aims at reducing overtreatment and burden of care in urological cancers, with a particular focus on kidney cancer.



Anand Swaminath

Dr. Swaminath is a clinician scientist and radiation oncologist at the Juravinski Cancer Centre, McMaster University, Hamilton, Canada. His clinical and research interests are in the application of new technologies in radiation therapy, specifically stereotactic radiation for a wide variety of indications including kidney, lung and liver cancer. He has a particular interest in radiation for kidney cancer - he is a member of the International Radiation Oncology Consortium of Kidney (IROCK) group, the Canadian Kidney Cancer Information System (CKCIS) steering committee, and the medical advisory board for Kidney Cancer Canada. He is also a co-PI on several local and national trials evaluating SBRT in both the primary and metastatic RCC setting.

BIOGRAPHIES



Emily Thain

Emily is an American Board Certified Genetic Counselor with clinical roles in the Bhalwani Familial Cancer Clinic at Princess Margaret Cancer Centre and the Elisabeth Raab Neurofibromatosis Clinic at Toronto General Hospital. She obtained her MSc Genetic Counselling degree from the University of Toronto. In addition to hereditary cancer, her interests include innovative models of genetics service delivery. She has led implementation of oncologist-ordered genetic testing with breast oncologists at Princess Margaret and has begun similar initiatives with GU oncologists. She is actively involved in teaching as a clinical supervisor and lecturer at the University of Toronto's MSc Genetic Counselling program.

WE WOULD LIKE TO THANK OUR SPONSORS

PLATINUM



GOLD



BRONZE



This event has been reviewed and approved by the Canadian Urological Association (CUA) as a Section 1 Group Learning Event, as defined by the Maintenance and Certification Program of the Royal College of Physicians and Surgeons, for a maximum of 12.5 hours.

Canadian **U**rological Association
The Voice of Urology in *Canada*



Association des **U**rologues du Canada
La voix de l'urologie au *Canada*

cua.org